Literature DB >> 3961473

The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic.

R D Gordon, G P Hodsman.   

Abstract

An excellent response to treatment with thiazide diuretic for twelve years is described in a patient with Gordon's Syndrome, the first to be reported from Scotland, and only the second to manifest the full clinical picture of short stature, hypertension, hyperkalaemia and hyperchloraemic acidosis without renal failure. The hypertension and biochemical abnormalities were reversed during therapy. Temporary withdrawal after seven years was followed by the immediate return of all the biochemical abnormalities, but not of the hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3961473     DOI: 10.1177/003693308603100114

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  17 in total

1.  SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction.

Authors:  Sung-Sen Yang; Yi-Fen Lo; Chin-Chen Wu; Shu-Wha Lin; Chien-Ju Yeh; Pauling Chu; Huey-Kang Sytwu; Shinichi Uchida; Sei Sasaki; Shih-Hua Lin
Journal:  J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 10.121

Review 2.  The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs.

Authors:  Gerardo Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

Review 3.  Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter.

Authors:  Benjamin Ko; Robert S Hoover
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-09       Impact factor: 2.894

Review 4.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

5.  Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1.

Authors:  Alberto C Vitari; Jacob Thastrup; Fatema H Rafiqi; Maria Deak; Nick A Morrice; Håkan K R Karlsson; Dario R Alessi
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

Review 6.  The WNKs: atypical protein kinases with pleiotropic actions.

Authors:  James A McCormick; David H Ellison
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

7.  Overexpression of the sodium chloride cotransporter is not sufficient to cause familial hyperkalemic hypertension.

Authors:  James A McCormick; Joshua H Nelson; Chao-Ling Yang; Joshua N Curry; David H Ellison
Journal:  Hypertension       Date:  2011-09-06       Impact factor: 10.190

8.  Aldosterone acutely stimulates NCC activity via a SPAK-mediated pathway.

Authors:  Benjamin Ko; Abinash C Mistry; Lauren Hanson; Rickta Mallick; Brandi M Wynne; Tiffany L Thai; James L Bailey; Janet D Klein; Robert S Hoover
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-05

Review 9.  Pharmacological targeting of SPAK kinase in disorders of impaired epithelial transport.

Authors:  Jinwei Zhang; Jason K Karimy; Eric Delpire; Kristopher T Kahle
Journal:  Expert Opin Ther Targets       Date:  2017-07-12       Impact factor: 6.902

10.  WNK1-related Familial Hyperkalemic Hypertension results from an increased expression of L-WNK1 specifically in the distal nephron.

Authors:  Emmanuelle Vidal-Petiot; Emilie Elvira-Matelot; Kerim Mutig; Christelle Soukaseum; Véronique Baudrie; Shengnan Wu; Lydie Cheval; Elizabeth Huc; Michèle Cambillau; Sebastian Bachmann; Alain Doucet; Xavier Jeunemaitre; Juliette Hadchouel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.